SELLAS Life Sciences Group, Inc (NASDAQ:SLS)
| Market Cap | 2.15B+510.9% |
| Revenue (ttm) | 0 |
| Net Income | -32.46M-23.6% |
| EPS | -0.21+35.4% |
| Shares Out | 186.03M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,560,582 |
| Open | 13.55 |
| Previous Close | 13.49 |
| Day's Range | 11.38 - 13.73 |
| 52-Week Range | 1.39 - 15.88 |
| Beta | 2.52 |
| Analysts | Buy |
| Price Target | 35.00(+203.16%) |
| Earnings Date | Nov 11, 2026 |
About SLS
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
$SLS stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in SLS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by SLS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
SLS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New SLS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to SLS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in SLS
| ETF | Est. Holding Size |
|---|---|
| XBIState Street SPDR S&P Biotech ETF | $124.60M |
| IWMiShares Russell 2000 ETF | $67.08M |
| IWOiShares Russell 2000 Growth ETF | $24.77M |
| VXFVanguard Extended Market ETF | $21.48M |
| VTWOVanguard Russell 2000 ETF | $10.60M |
| IWCiShares Micro-Cap ETF | $8.94M |
Estimated from each fund’s disclosed top holdings × AUM
SLS Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from SLS’s recent data — informational, not investment advice
Recent Insider Activity
No Form 4 filings in the last 90 days.